nodes	percent_of_prediction	percent_of_DWPC	metapath
Alfentanil—CYP3A7—Ifosfamide—testicular cancer	0.149	0.18	CbGbCtD
Alfentanil—CYP3A7-CYP3A51P—Ifosfamide—testicular cancer	0.149	0.18	CbGbCtD
Alfentanil—CYP3A5—Ifosfamide—testicular cancer	0.112	0.135	CbGbCtD
Alfentanil—ABCB1—Dactinomycin—testicular cancer	0.0615	0.0746	CbGbCtD
Alfentanil—CYP3A5—Etoposide—testicular cancer	0.0533	0.0647	CbGbCtD
Alfentanil—ALB—Methotrexate—testicular cancer	0.0438	0.0532	CbGbCtD
Alfentanil—CYP3A4—Ifosfamide—testicular cancer	0.0435	0.0528	CbGbCtD
Alfentanil—ABCB1—Vinblastine—testicular cancer	0.0385	0.0467	CbGbCtD
Alfentanil—ABCB1—Cisplatin—testicular cancer	0.0353	0.0428	CbGbCtD
Alfentanil—ABCB1—Etoposide—testicular cancer	0.0347	0.0421	CbGbCtD
Alfentanil—ABCB1—Doxorubicin—testicular cancer	0.0237	0.0287	CbGbCtD
Alfentanil—CYP3A4—Vinblastine—testicular cancer	0.0231	0.028	CbGbCtD
Alfentanil—ABCB1—Methotrexate—testicular cancer	0.0229	0.0278	CbGbCtD
Alfentanil—CYP3A4—Etoposide—testicular cancer	0.0208	0.0252	CbGbCtD
Alfentanil—CYP3A4—Doxorubicin—testicular cancer	0.0142	0.0172	CbGbCtD
Alfentanil—Vision blurred—Ifosfamide—testicular cancer	0.000717	0.00408	CcSEcCtD
Alfentanil—Hiccups—Doxorubicin—testicular cancer	0.000713	0.00406	CcSEcCtD
Alfentanil—Feeling abnormal—Vinblastine—testicular cancer	0.000709	0.00404	CcSEcCtD
Alfentanil—Eye disorder—Cisplatin—testicular cancer	0.000704	0.00401	CcSEcCtD
Alfentanil—Cardiac disorder—Cisplatin—testicular cancer	0.000699	0.00398	CcSEcCtD
Alfentanil—Agitation—Ifosfamide—testicular cancer	0.000699	0.00398	CcSEcCtD
Alfentanil—Hypersensitivity—Chlorambucil—testicular cancer	0.000692	0.00394	CcSEcCtD
Alfentanil—Immune system disorder—Cisplatin—testicular cancer	0.000681	0.00388	CcSEcCtD
Alfentanil—Mediastinal disorder—Cisplatin—testicular cancer	0.000679	0.00387	CcSEcCtD
Alfentanil—Hypotension—Bleomycin—testicular cancer	0.000679	0.00387	CcSEcCtD
Alfentanil—Asthenia—Chlorambucil—testicular cancer	0.000674	0.00384	CcSEcCtD
Alfentanil—Arrhythmia—Cisplatin—testicular cancer	0.000673	0.00383	CcSEcCtD
Alfentanil—Pruritus—Chlorambucil—testicular cancer	0.000664	0.00378	CcSEcCtD
Alfentanil—Cough—Ifosfamide—testicular cancer	0.000664	0.00378	CcSEcCtD
Alfentanil—Convulsion—Ifosfamide—testicular cancer	0.000659	0.00375	CcSEcCtD
Alfentanil—Hypertension—Ifosfamide—testicular cancer	0.000657	0.00374	CcSEcCtD
Alfentanil—Erythema—Cisplatin—testicular cancer	0.000656	0.00374	CcSEcCtD
Alfentanil—Eye disorder—Etoposide—testicular cancer	0.000645	0.00367	CcSEcCtD
Alfentanil—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.000643	0.00366	CcSEcCtD
Alfentanil—Cardiac disorder—Etoposide—testicular cancer	0.000641	0.00365	CcSEcCtD
Alfentanil—Hypersensitivity—Vinblastine—testicular cancer	0.000634	0.00361	CcSEcCtD
Alfentanil—Visual disturbance—Methotrexate—testicular cancer	0.000631	0.00359	CcSEcCtD
Alfentanil—Angiopathy—Etoposide—testicular cancer	0.000626	0.00357	CcSEcCtD
Alfentanil—Confusional state—Ifosfamide—testicular cancer	0.000626	0.00357	CcSEcCtD
Alfentanil—Immune system disorder—Etoposide—testicular cancer	0.000624	0.00355	CcSEcCtD
Alfentanil—Mediastinal disorder—Etoposide—testicular cancer	0.000622	0.00354	CcSEcCtD
Alfentanil—Pain—Bleomycin—testicular cancer	0.000621	0.00354	CcSEcCtD
Alfentanil—Anaphylactic shock—Ifosfamide—testicular cancer	0.000621	0.00354	CcSEcCtD
Alfentanil—Chills—Etoposide—testicular cancer	0.000619	0.00353	CcSEcCtD
Alfentanil—Vision blurred—Cisplatin—testicular cancer	0.000618	0.00352	CcSEcCtD
Alfentanil—Anaphylactoid reaction—Methotrexate—testicular cancer	0.000618	0.00352	CcSEcCtD
Alfentanil—Asthenia—Vinblastine—testicular cancer	0.000617	0.00352	CcSEcCtD
Alfentanil—Nervous system disorder—Ifosfamide—testicular cancer	0.000609	0.00347	CcSEcCtD
Alfentanil—Skin disorder—Ifosfamide—testicular cancer	0.000603	0.00343	CcSEcCtD
Alfentanil—Hyperhidrosis—Ifosfamide—testicular cancer	0.0006	0.00342	CcSEcCtD
Alfentanil—Feeling abnormal—Bleomycin—testicular cancer	0.000599	0.00341	CcSEcCtD
Alfentanil—Vomiting—Chlorambucil—testicular cancer	0.000597	0.0034	CcSEcCtD
Alfentanil—Fatigue—Dactinomycin—testicular cancer	0.000584	0.00333	CcSEcCtD
Alfentanil—Hypotension—Ifosfamide—testicular cancer	0.00058	0.0033	CcSEcCtD
Alfentanil—Pain—Dactinomycin—testicular cancer	0.000579	0.0033	CcSEcCtD
Alfentanil—Anaphylactoid reaction—Epirubicin—testicular cancer	0.000578	0.00329	CcSEcCtD
Alfentanil—Urticaria—Bleomycin—testicular cancer	0.000577	0.00329	CcSEcCtD
Alfentanil—Body temperature increased—Bleomycin—testicular cancer	0.000574	0.00327	CcSEcCtD
Alfentanil—Dizziness—Vinblastine—testicular cancer	0.000569	0.00324	CcSEcCtD
Alfentanil—Convulsion—Cisplatin—testicular cancer	0.000568	0.00324	CcSEcCtD
Alfentanil—Feeling abnormal—Dactinomycin—testicular cancer	0.000558	0.00318	CcSEcCtD
Alfentanil—Nausea—Chlorambucil—testicular cancer	0.000558	0.00318	CcSEcCtD
Alfentanil—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.000555	0.00316	CcSEcCtD
Alfentanil—Somnolence—Ifosfamide—testicular cancer	0.000552	0.00314	CcSEcCtD
Alfentanil—Vomiting—Vinblastine—testicular cancer	0.000547	0.00312	CcSEcCtD
Alfentanil—Headache—Vinblastine—testicular cancer	0.000539	0.00307	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.000536	0.00305	CcSEcCtD
Alfentanil—Body temperature increased—Dactinomycin—testicular cancer	0.000536	0.00305	CcSEcCtD
Alfentanil—Fatigue—Ifosfamide—testicular cancer	0.000535	0.00305	CcSEcCtD
Alfentanil—Anaphylactic shock—Cisplatin—testicular cancer	0.000535	0.00305	CcSEcCtD
Alfentanil—Hypersensitivity—Bleomycin—testicular cancer	0.000535	0.00305	CcSEcCtD
Alfentanil—Anaphylactoid reaction—Doxorubicin—testicular cancer	0.000535	0.00305	CcSEcCtD
Alfentanil—Cardiac arrest—Epirubicin—testicular cancer	0.000532	0.00303	CcSEcCtD
Alfentanil—Pain—Ifosfamide—testicular cancer	0.000531	0.00302	CcSEcCtD
Alfentanil—Loss of consciousness—Etoposide—testicular cancer	0.000528	0.00301	CcSEcCtD
Alfentanil—Nervous system disorder—Cisplatin—testicular cancer	0.000525	0.00299	CcSEcCtD
Alfentanil—Cough—Etoposide—testicular cancer	0.000524	0.00299	CcSEcCtD
Alfentanil—Tachycardia—Cisplatin—testicular cancer	0.000522	0.00298	CcSEcCtD
Alfentanil—Asthenia—Bleomycin—testicular cancer	0.000521	0.00297	CcSEcCtD
Alfentanil—Convulsion—Etoposide—testicular cancer	0.000521	0.00297	CcSEcCtD
Alfentanil—Skin disorder—Cisplatin—testicular cancer	0.00052	0.00296	CcSEcCtD
Alfentanil—Hypertension—Etoposide—testicular cancer	0.000519	0.00295	CcSEcCtD
Alfentanil—Hyperhidrosis—Cisplatin—testicular cancer	0.000518	0.00295	CcSEcCtD
Alfentanil—Pruritus—Bleomycin—testicular cancer	0.000514	0.00293	CcSEcCtD
Alfentanil—Feeling abnormal—Ifosfamide—testicular cancer	0.000512	0.00291	CcSEcCtD
Alfentanil—Nausea—Vinblastine—testicular cancer	0.000511	0.00291	CcSEcCtD
Alfentanil—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.000508	0.00289	CcSEcCtD
Alfentanil—Hypotension—Cisplatin—testicular cancer	0.0005	0.00285	CcSEcCtD
Alfentanil—Hypersensitivity—Dactinomycin—testicular cancer	0.000499	0.00284	CcSEcCtD
Alfentanil—Confusional state—Etoposide—testicular cancer	0.000495	0.00282	CcSEcCtD
Alfentanil—Urticaria—Ifosfamide—testicular cancer	0.000493	0.00281	CcSEcCtD
Alfentanil—Cardiac arrest—Doxorubicin—testicular cancer	0.000492	0.0028	CcSEcCtD
Alfentanil—Body temperature increased—Ifosfamide—testicular cancer	0.000491	0.0028	CcSEcCtD
Alfentanil—Anaphylactic shock—Etoposide—testicular cancer	0.00049	0.00279	CcSEcCtD
Alfentanil—Asthenia—Dactinomycin—testicular cancer	0.000486	0.00277	CcSEcCtD
Alfentanil—Tachycardia—Etoposide—testicular cancer	0.000479	0.00273	CcSEcCtD
Alfentanil—Skin disorder—Etoposide—testicular cancer	0.000476	0.00271	CcSEcCtD
Alfentanil—Hyperhidrosis—Etoposide—testicular cancer	0.000474	0.0027	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000462	0.00263	CcSEcCtD
Alfentanil—Vomiting—Bleomycin—testicular cancer	0.000462	0.00263	CcSEcCtD
Alfentanil—Drowsiness—Methotrexate—testicular cancer	0.000461	0.00262	CcSEcCtD
Alfentanil—Hypotension—Etoposide—testicular cancer	0.000458	0.00261	CcSEcCtD
Alfentanil—Rash—Bleomycin—testicular cancer	0.000458	0.00261	CcSEcCtD
Alfentanil—Pain—Cisplatin—testicular cancer	0.000458	0.00261	CcSEcCtD
Alfentanil—Dermatitis—Bleomycin—testicular cancer	0.000458	0.00261	CcSEcCtD
Alfentanil—Hypersensitivity—Ifosfamide—testicular cancer	0.000458	0.00261	CcSEcCtD
Alfentanil—Asthenia—Ifosfamide—testicular cancer	0.000446	0.00254	CcSEcCtD
Alfentanil—Feeling abnormal—Cisplatin—testicular cancer	0.000441	0.00251	CcSEcCtD
Alfentanil—Pruritus—Ifosfamide—testicular cancer	0.000439	0.0025	CcSEcCtD
Alfentanil—Somnolence—Etoposide—testicular cancer	0.000436	0.00248	CcSEcCtD
Alfentanil—Epistaxis—Methotrexate—testicular cancer	0.000434	0.00247	CcSEcCtD
Alfentanil—Nausea—Bleomycin—testicular cancer	0.000432	0.00246	CcSEcCtD
Alfentanil—Drowsiness—Epirubicin—testicular cancer	0.000431	0.00245	CcSEcCtD
Alfentanil—Vomiting—Dactinomycin—testicular cancer	0.000431	0.00245	CcSEcCtD
Alfentanil—Rash—Dactinomycin—testicular cancer	0.000427	0.00243	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Etoposide—testicular cancer	0.000423	0.00241	CcSEcCtD
Alfentanil—Body temperature increased—Cisplatin—testicular cancer	0.000423	0.00241	CcSEcCtD
Alfentanil—Fatigue—Etoposide—testicular cancer	0.000423	0.00241	CcSEcCtD
Alfentanil—Pain—Etoposide—testicular cancer	0.000419	0.00239	CcSEcCtD
Alfentanil—Dizziness—Ifosfamide—testicular cancer	0.000411	0.00234	CcSEcCtD
Alfentanil—Epistaxis—Epirubicin—testicular cancer	0.000407	0.00232	CcSEcCtD
Alfentanil—Feeling abnormal—Etoposide—testicular cancer	0.000404	0.0023	CcSEcCtD
Alfentanil—Nausea—Dactinomycin—testicular cancer	0.000403	0.00229	CcSEcCtD
Alfentanil—Drowsiness—Doxorubicin—testicular cancer	0.000399	0.00227	CcSEcCtD
Alfentanil—Visual impairment—Methotrexate—testicular cancer	0.000398	0.00227	CcSEcCtD
Alfentanil—Vomiting—Ifosfamide—testicular cancer	0.000395	0.00225	CcSEcCtD
Alfentanil—Hypersensitivity—Cisplatin—testicular cancer	0.000394	0.00225	CcSEcCtD
Alfentanil—Bradycardia—Epirubicin—testicular cancer	0.000394	0.00224	CcSEcCtD
Alfentanil—Rash—Ifosfamide—testicular cancer	0.000392	0.00223	CcSEcCtD
Alfentanil—Dermatitis—Ifosfamide—testicular cancer	0.000391	0.00223	CcSEcCtD
Alfentanil—Urticaria—Etoposide—testicular cancer	0.00039	0.00222	CcSEcCtD
Alfentanil—Body temperature increased—Etoposide—testicular cancer	0.000388	0.00221	CcSEcCtD
Alfentanil—Eye disorder—Methotrexate—testicular cancer	0.000386	0.0022	CcSEcCtD
Alfentanil—Asthenia—Cisplatin—testicular cancer	0.000384	0.00219	CcSEcCtD
Alfentanil—Cardiac disorder—Methotrexate—testicular cancer	0.000384	0.00219	CcSEcCtD
Alfentanil—Connective tissue disorder—Epirubicin—testicular cancer	0.00038	0.00217	CcSEcCtD
Alfentanil—Epistaxis—Doxorubicin—testicular cancer	0.000376	0.00214	CcSEcCtD
Alfentanil—Angiopathy—Methotrexate—testicular cancer	0.000375	0.00214	CcSEcCtD
Alfentanil—Immune system disorder—Methotrexate—testicular cancer	0.000373	0.00213	CcSEcCtD
Alfentanil—Visual impairment—Epirubicin—testicular cancer	0.000373	0.00212	CcSEcCtD
Alfentanil—Mediastinal disorder—Methotrexate—testicular cancer	0.000373	0.00212	CcSEcCtD
Alfentanil—Chills—Methotrexate—testicular cancer	0.000371	0.00211	CcSEcCtD
Alfentanil—Nausea—Ifosfamide—testicular cancer	0.000369	0.0021	CcSEcCtD
Alfentanil—Bradycardia—Doxorubicin—testicular cancer	0.000365	0.00208	CcSEcCtD
Alfentanil—Mental disorder—Methotrexate—testicular cancer	0.000362	0.00206	CcSEcCtD
Alfentanil—Eye disorder—Epirubicin—testicular cancer	0.000362	0.00206	CcSEcCtD
Alfentanil—Hypersensitivity—Etoposide—testicular cancer	0.000361	0.00206	CcSEcCtD
Alfentanil—Erythema—Methotrexate—testicular cancer	0.00036	0.00205	CcSEcCtD
Alfentanil—Cardiac disorder—Epirubicin—testicular cancer	0.000359	0.00205	CcSEcCtD
Alfentanil—Asthenia—Etoposide—testicular cancer	0.000352	0.002	CcSEcCtD
Alfentanil—Connective tissue disorder—Doxorubicin—testicular cancer	0.000352	0.002	CcSEcCtD
Alfentanil—Angiopathy—Epirubicin—testicular cancer	0.000351	0.002	CcSEcCtD
Alfentanil—Immune system disorder—Epirubicin—testicular cancer	0.00035	0.00199	CcSEcCtD
Alfentanil—Mediastinal disorder—Epirubicin—testicular cancer	0.000349	0.00199	CcSEcCtD
Alfentanil—Chills—Epirubicin—testicular cancer	0.000347	0.00198	CcSEcCtD
Alfentanil—Pruritus—Etoposide—testicular cancer	0.000347	0.00198	CcSEcCtD
Alfentanil—Arrhythmia—Epirubicin—testicular cancer	0.000346	0.00197	CcSEcCtD
Alfentanil—Visual impairment—Doxorubicin—testicular cancer	0.000345	0.00197	CcSEcCtD
Alfentanil—Vomiting—Cisplatin—testicular cancer	0.00034	0.00194	CcSEcCtD
Alfentanil—Vision blurred—Methotrexate—testicular cancer	0.000339	0.00193	CcSEcCtD
Alfentanil—Mental disorder—Epirubicin—testicular cancer	0.000339	0.00193	CcSEcCtD
Alfentanil—Rash—Cisplatin—testicular cancer	0.000338	0.00192	CcSEcCtD
Alfentanil—Dermatitis—Cisplatin—testicular cancer	0.000337	0.00192	CcSEcCtD
Alfentanil—Erythema—Epirubicin—testicular cancer	0.000337	0.00192	CcSEcCtD
Alfentanil—Eye disorder—Doxorubicin—testicular cancer	0.000335	0.00191	CcSEcCtD
Alfentanil—Cardiac disorder—Doxorubicin—testicular cancer	0.000332	0.00189	CcSEcCtD
Alfentanil—Angiopathy—Doxorubicin—testicular cancer	0.000325	0.00185	CcSEcCtD
Alfentanil—Dizziness—Etoposide—testicular cancer	0.000324	0.00185	CcSEcCtD
Alfentanil—Immune system disorder—Doxorubicin—testicular cancer	0.000323	0.00184	CcSEcCtD
Alfentanil—Mediastinal disorder—Doxorubicin—testicular cancer	0.000323	0.00184	CcSEcCtD
Alfentanil—Chills—Doxorubicin—testicular cancer	0.000321	0.00183	CcSEcCtD
Alfentanil—Arrhythmia—Doxorubicin—testicular cancer	0.00032	0.00182	CcSEcCtD
Alfentanil—Nausea—Cisplatin—testicular cancer	0.000318	0.00181	CcSEcCtD
Alfentanil—Vision blurred—Epirubicin—testicular cancer	0.000317	0.00181	CcSEcCtD
Alfentanil—Cough—Methotrexate—testicular cancer	0.000314	0.00179	CcSEcCtD
Alfentanil—Mental disorder—Doxorubicin—testicular cancer	0.000314	0.00179	CcSEcCtD
Alfentanil—Convulsion—Methotrexate—testicular cancer	0.000312	0.00178	CcSEcCtD
Alfentanil—Vomiting—Etoposide—testicular cancer	0.000312	0.00178	CcSEcCtD
Alfentanil—Erythema—Doxorubicin—testicular cancer	0.000312	0.00178	CcSEcCtD
Alfentanil—Agitation—Epirubicin—testicular cancer	0.00031	0.00176	CcSEcCtD
Alfentanil—Rash—Etoposide—testicular cancer	0.000309	0.00176	CcSEcCtD
Alfentanil—Dermatitis—Etoposide—testicular cancer	0.000309	0.00176	CcSEcCtD
Alfentanil—Headache—Etoposide—testicular cancer	0.000307	0.00175	CcSEcCtD
Alfentanil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000304	0.00173	CcSEcCtD
Alfentanil—Confusional state—Methotrexate—testicular cancer	0.000296	0.00169	CcSEcCtD
Alfentanil—Loss of consciousness—Epirubicin—testicular cancer	0.000296	0.00169	CcSEcCtD
Alfentanil—Cough—Epirubicin—testicular cancer	0.000294	0.00167	CcSEcCtD
Alfentanil—Anaphylactic shock—Methotrexate—testicular cancer	0.000294	0.00167	CcSEcCtD
Alfentanil—Vision blurred—Doxorubicin—testicular cancer	0.000294	0.00167	CcSEcCtD
Alfentanil—Convulsion—Epirubicin—testicular cancer	0.000292	0.00166	CcSEcCtD
Alfentanil—Nausea—Etoposide—testicular cancer	0.000291	0.00166	CcSEcCtD
Alfentanil—Hypertension—Epirubicin—testicular cancer	0.000291	0.00166	CcSEcCtD
Alfentanil—Nervous system disorder—Methotrexate—testicular cancer	0.000288	0.00164	CcSEcCtD
Alfentanil—Agitation—Doxorubicin—testicular cancer	0.000286	0.00163	CcSEcCtD
Alfentanil—Skin disorder—Methotrexate—testicular cancer	0.000285	0.00163	CcSEcCtD
Alfentanil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000285	0.00162	CcSEcCtD
Alfentanil—Hyperhidrosis—Methotrexate—testicular cancer	0.000284	0.00162	CcSEcCtD
Alfentanil—Confusional state—Epirubicin—testicular cancer	0.000277	0.00158	CcSEcCtD
Alfentanil—Anaphylactic shock—Epirubicin—testicular cancer	0.000275	0.00157	CcSEcCtD
Alfentanil—Hypotension—Methotrexate—testicular cancer	0.000275	0.00156	CcSEcCtD
Alfentanil—Loss of consciousness—Doxorubicin—testicular cancer	0.000274	0.00156	CcSEcCtD
Alfentanil—Cough—Doxorubicin—testicular cancer	0.000272	0.00155	CcSEcCtD
Alfentanil—Convulsion—Doxorubicin—testicular cancer	0.00027	0.00154	CcSEcCtD
Alfentanil—Nervous system disorder—Epirubicin—testicular cancer	0.00027	0.00154	CcSEcCtD
Alfentanil—Hypertension—Doxorubicin—testicular cancer	0.000269	0.00153	CcSEcCtD
Alfentanil—Tachycardia—Epirubicin—testicular cancer	0.000268	0.00153	CcSEcCtD
Alfentanil—Skin disorder—Epirubicin—testicular cancer	0.000267	0.00152	CcSEcCtD
Alfentanil—Hyperhidrosis—Epirubicin—testicular cancer	0.000266	0.00151	CcSEcCtD
Alfentanil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000264	0.0015	CcSEcCtD
Alfentanil—Somnolence—Methotrexate—testicular cancer	0.000261	0.00149	CcSEcCtD
Alfentanil—Hypotension—Epirubicin—testicular cancer	0.000257	0.00146	CcSEcCtD
Alfentanil—Confusional state—Doxorubicin—testicular cancer	0.000256	0.00146	CcSEcCtD
Alfentanil—Anaphylactic shock—Doxorubicin—testicular cancer	0.000254	0.00145	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000254	0.00144	CcSEcCtD
Alfentanil—Fatigue—Methotrexate—testicular cancer	0.000253	0.00144	CcSEcCtD
Alfentanil—Pain—Methotrexate—testicular cancer	0.000251	0.00143	CcSEcCtD
Alfentanil—Nervous system disorder—Doxorubicin—testicular cancer	0.000249	0.00142	CcSEcCtD
Alfentanil—Tachycardia—Doxorubicin—testicular cancer	0.000248	0.00141	CcSEcCtD
Alfentanil—Skin disorder—Doxorubicin—testicular cancer	0.000247	0.00141	CcSEcCtD
Alfentanil—Hyperhidrosis—Doxorubicin—testicular cancer	0.000246	0.0014	CcSEcCtD
Alfentanil—Somnolence—Epirubicin—testicular cancer	0.000244	0.00139	CcSEcCtD
Alfentanil—Feeling abnormal—Methotrexate—testicular cancer	0.000242	0.00138	CcSEcCtD
Alfentanil—Hypotension—Doxorubicin—testicular cancer	0.000238	0.00135	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000237	0.00135	CcSEcCtD
Alfentanil—Fatigue—Epirubicin—testicular cancer	0.000237	0.00135	CcSEcCtD
Alfentanil—Pain—Epirubicin—testicular cancer	0.000235	0.00134	CcSEcCtD
Alfentanil—Urticaria—Methotrexate—testicular cancer	0.000233	0.00133	CcSEcCtD
Alfentanil—Body temperature increased—Methotrexate—testicular cancer	0.000232	0.00132	CcSEcCtD
Alfentanil—Feeling abnormal—Epirubicin—testicular cancer	0.000227	0.00129	CcSEcCtD
Alfentanil—Somnolence—Doxorubicin—testicular cancer	0.000226	0.00129	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.00022	0.00125	CcSEcCtD
Alfentanil—Fatigue—Doxorubicin—testicular cancer	0.000219	0.00125	CcSEcCtD
Alfentanil—Urticaria—Epirubicin—testicular cancer	0.000218	0.00124	CcSEcCtD
Alfentanil—Pain—Doxorubicin—testicular cancer	0.000218	0.00124	CcSEcCtD
Alfentanil—Body temperature increased—Epirubicin—testicular cancer	0.000217	0.00124	CcSEcCtD
Alfentanil—Hypersensitivity—Methotrexate—testicular cancer	0.000216	0.00123	CcSEcCtD
Alfentanil—Asthenia—Methotrexate—testicular cancer	0.000211	0.0012	CcSEcCtD
Alfentanil—Feeling abnormal—Doxorubicin—testicular cancer	0.00021	0.00119	CcSEcCtD
Alfentanil—Pruritus—Methotrexate—testicular cancer	0.000208	0.00118	CcSEcCtD
Alfentanil—Hypersensitivity—Epirubicin—testicular cancer	0.000203	0.00115	CcSEcCtD
Alfentanil—Urticaria—Doxorubicin—testicular cancer	0.000202	0.00115	CcSEcCtD
Alfentanil—Body temperature increased—Doxorubicin—testicular cancer	0.000201	0.00115	CcSEcCtD
Alfentanil—Asthenia—Epirubicin—testicular cancer	0.000197	0.00112	CcSEcCtD
Alfentanil—Pruritus—Epirubicin—testicular cancer	0.000195	0.00111	CcSEcCtD
Alfentanil—Dizziness—Methotrexate—testicular cancer	0.000194	0.00111	CcSEcCtD
Alfentanil—Hypersensitivity—Doxorubicin—testicular cancer	0.000187	0.00107	CcSEcCtD
Alfentanil—Vomiting—Methotrexate—testicular cancer	0.000187	0.00106	CcSEcCtD
Alfentanil—Rash—Methotrexate—testicular cancer	0.000185	0.00105	CcSEcCtD
Alfentanil—Dermatitis—Methotrexate—testicular cancer	0.000185	0.00105	CcSEcCtD
Alfentanil—Headache—Methotrexate—testicular cancer	0.000184	0.00105	CcSEcCtD
Alfentanil—Asthenia—Doxorubicin—testicular cancer	0.000183	0.00104	CcSEcCtD
Alfentanil—Dizziness—Epirubicin—testicular cancer	0.000182	0.00104	CcSEcCtD
Alfentanil—Pruritus—Doxorubicin—testicular cancer	0.00018	0.00102	CcSEcCtD
Alfentanil—Vomiting—Epirubicin—testicular cancer	0.000175	0.000995	CcSEcCtD
Alfentanil—Nausea—Methotrexate—testicular cancer	0.000175	0.000994	CcSEcCtD
Alfentanil—Rash—Epirubicin—testicular cancer	0.000173	0.000987	CcSEcCtD
Alfentanil—Dermatitis—Epirubicin—testicular cancer	0.000173	0.000986	CcSEcCtD
Alfentanil—Headache—Epirubicin—testicular cancer	0.000172	0.000981	CcSEcCtD
Alfentanil—Dizziness—Doxorubicin—testicular cancer	0.000168	0.000958	CcSEcCtD
Alfentanil—Nausea—Epirubicin—testicular cancer	0.000163	0.00093	CcSEcCtD
Alfentanil—Vomiting—Doxorubicin—testicular cancer	0.000162	0.000921	CcSEcCtD
Alfentanil—Rash—Doxorubicin—testicular cancer	0.00016	0.000913	CcSEcCtD
Alfentanil—Dermatitis—Doxorubicin—testicular cancer	0.00016	0.000913	CcSEcCtD
Alfentanil—Headache—Doxorubicin—testicular cancer	0.000159	0.000908	CcSEcCtD
Alfentanil—Nausea—Doxorubicin—testicular cancer	0.000151	0.00086	CcSEcCtD
